Get startedLog in
    Picture of Sellas Life Sciences logo

    SLS — Sellas Life Sciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapNeutral
    All News

    Brief: Sellas Announces First Patient Dosed In Phase Ib/II Trial Of SLS009 (GFH009) In Relapsed/Refractory Peripheral T-Cell Lymphomas

    Picture of Sellas Life Sciences logoSellas Life Sciences
    11/10/2023 13:46
    Oct 11 (Reuters) - Sellas Life Sciences Group Inc
 SLS.O :
    * SELLAS ANNOUNCES FIRST PATIENT DOSED IN PHASE IB/II TRIAL
OF
SLS009 (GFH009) IN RELAPSED/REFRACTORY PERIPHERAL T-CELL
LYMPHOMAS

Source text for Eikon:  ID:nGNX2S3bBs 
Further company coverage:  SLS.O 

 ((Reuters.Briefs@thomsonreuters.com))

    Recent news on Sellas Life Sciences

    See all news